BARICITINIB IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

被引：1

作者：

Wallace, D. J. ^{[1
]}

Furie, R. A. ^{[2
]}

Tanaka, Y. ^{[3
]}

Kalunian, K. C. ^{[4
]}

Mosca, M. ^{[5
]}

Petri, M. A. ^{[6
]}

Dorner, T. ^{[7
]}

Cardiel, M. H. ^{[8
]}

Bruce, I. N. ^{[9
]}

Gomez, E. ^{[10
]}

Carmack, T. ^{[10
]}

Janes, J. M. ^{[10
]}

Linnik, M. D. ^{[10
]}

Silk, M. ^{[10
]}

Hoffman, R. ^{[10
]}

机构：

[1] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[2] Hofstra Northwell Sch Med, New York, NY USA

[3] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka, Japan

[4] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA

[5] Univ Pisa, Pisa, Italy

[6] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[7] Charite Univ Med Berlin, Berlin, Germany

[8] Ctr Invest Clin Morelia SC, Morelia, Michoacan, Mexico

[9] Univ Manchester, Manchester, Lancs, England

[10] Eli Lilly & Co, Indianapolis, IN 46285 USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷

关键词：

D O I：

10.1136/annrheumdis-2018-eular.1918

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0019

引用

页码：59 / 59

页数：1

共 50 条

[1] Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Wallace, Daniel J.
Furie, Richard A.
Tanaka, Yoshiya
Kalunian, Kenneth C.
Mosca, Marta
Petri, Michelle A.
Doerner, Thomas
Cardiel, Mario H.
Bruce, Ian N.
Gomez, Elisa
Carmack, Tara
DeLozier, Amy M.
Janes, Jonathan M.
Linnik, Matthew D.
de Bono, Stephanie
Silk, Maria E.
Hoffman, Robert W.
[J]. LANCET, 2018, 392 (10143): : 222 - 231
[2] Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Wallace, Daniel J.
Furie, Richard
Tanaka, Yoshiya
Kalunian, Kenneth C.
Mosca, Marta
Petri, Michelle
Dorner, Thomas
Cardiel, Mario H.
Bruce, Ian N.
Gomez, Elisa
DeLozier, Amy M.
Janes, Jonathan
Linnik, Matthew D.
de Bono, Stephanie
Silk, Maria E.
Hoffman, Robert W.
[J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
[3] Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
Petri, Michelle
Bruce, Ian N.
Doerner, Thomas
Tanaka, Yoshiya
Morand, Eric F.
Kalunian, Kenneth C.
Cardiel, Mario H.
Silk, Maria E.
Dickson, Christina L.
Meszaros, Gabriella
Zhang, Lu
Jia, Bochao
Zhao, Youna
McVeigh, Conor J.
Mosca, Marta
[J]. LANCET, 2023, 401 (10381): : 1011 - 1019
[4] Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
Morand, Eric F.
Vital, Edward M.
Petri, Michelle
van Vollenhoven, Ronald
Wallace, Daniel J.
Mosca, Marta
Furie, Richard A.
Silk, Maria E.
Dickson, Christina L.
Meszaros, Gabriella
Jia, Bochao
Crowe, Brenda
Torre, Inmaculada de la
Doerner, Thomas
[J]. LANCET, 2023, 401 (10381): : 1001 - 1010
[5] Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial (vol 392, pg 222, 2018)
Wallace, D. J.
Furie, R. A.
Tanaka, Y.
[J]. LANCET, 2018, 392 (10146): : 476 - 476
[6] POOLED SAFETY ANALYSIS OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THREE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIALS
Dorner, T.
Tanaka, Y.
Mosca, M.
Bruce, I. N.
Cardiel, M.
Morand, E. F.
Petri, M. A.
Silk, M.
Dickson, C.
Meszaros, G.
Issa, M.
Zhang, L.
Wallace, D. J.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 639 - 639
[7] EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM TWO RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDIES
Morand, E. F.
Tanaka, Y.
Furie, R.
Vital, E.
van Vollenhoven, R.
Kalunian, K.
Mosca, M.
Doerner, T.
Wallace, D. J.
Silk, M.
Dickson, C.
De la Torre, I.
Meszaros, G.
Jia, B.
Crowe, B.
Petri, M. A.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 327 - 328
[8] Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial
Wu, Di
Li, Jing
Xu, Dong
Merrill, Joan T.
van Vollenhoven, Ronald F.
Liu, Yi
Hu, Jiankang
Li, Yang
Li, Fen
Huang, Chenghui
Wang, Guochun
Li, Xiaomei
Zhao, Jianhong
Zhao, Dongbao
Huang, Cibo
Liu, Huaxiang
Wei, Wei
Shi, Guixiu
Lu, Fuai
Zuo, Xiaoxia
Bi, Liqi
Li, Zhijun
Wang, Xiaoxia
Zhang, Miaojia
Tie, Ning
Li, Juan
Mo, Hanyou
Fang, Jianmin
Bao, Chunde
Zhang, Fengchun
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (04) : 475 - 487
[9] Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study
Alvarez-Nemegyei, J
Cobarrubias-Cobos, A
Escalante-Triay, F
Sosa-Munoz, J
Miranda, JM
Jara, LJ
[J]. LUPUS, 1998, 7 (06) : 414 - 419
[10] Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial
Doerner, Thomas
van Vollenhoven, Ronald F.
Doria, Andrea
Jia, Bochao
Terres, Jorge A. Ross
Silk, Maria E.
de Bono, Stephanie
Fischer, Peter
Wallace, Daniel J.
[J]. ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)

← 1 2 3 4 5 →